TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03119883

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5-Carbon C 13-labeled Glutamine
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of bone marrow aspirate samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of bone marrow aspirate samples

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Uniformly-labeled [13C]glucose
Description: Given IV
Study: NCT00390078

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA-mBN32
Description: 3 immunizations: 1x 10E8_TCID50 MVA-mBN32

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: IMVAMUNE
Description: 3 immunizations: 1x 10E8_TCID50 IMVAMUNE
Study: NCT04597970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cTACE-HAIC
Description: transarterial chemoembolization (TACE) plus Hepatic Arterial Infusion Chemotherapy (HAIC) with oxaliplatin and raltitrexed for Barcelona stage C hepatocellular carcinoma (HCC)
Study: NCT00113815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topiramate
Description: 15 mg/kg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topiramate
Description: 5 mg/kg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topiramate
Description: 25 mg/kg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo
Study: NCT01833689

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: food consumption
Description: Reference food The reference food is 50 g glucose powder dissolved in 250ml water~Test foods The test foods are prepared according to manufacturer's instructions, representing the food as normally consumed. The test foods are consumed once only on separate occasions as a portion providing 50g of available carbohydrate.~Breakfast cereals should be consumed with 150 ml milk which is additional to the 50 g available carbohydrate in the cereal. In testing breakfast cereals, the reference food must also be consumed with an additional 150 ml milk.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: food consumption
Description: Reference food The reference food is 50 g glucose powder dissolved in 250ml water~Test foods The test foods are prepared according to manufacturer's instructions, representing the food as normally consumed. The test foods are consumed once only on separate occasions as a portion providing 50g of available carbohydrate.~Breakfast cereals should be consumed with 150 ml milk which is additional to the 50 g available carbohydrate in the cereal. In testing breakfast cereals, the reference food must also be consumed with an additional 150 ml milk.
Study: NCT01754415

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hydraulic resistance circuit training
Description: 12 weeks (3 times per week, 40 min circuit) of hydraulic resistance circuit training that consisted of 10 types of equipments for different part of strength training.
Study: NCT04476212

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical antibiotic prophylaxis
Description: The surgical wound will be irrigated with an antibiotic solution, and then we will apply the same solution using gauze for two minutes on the wound
Study: NCT04608747

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tahini
Description: Fifty grams of tahini were consumed by 20 healthy males
Study: NCT02514200

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Topography-based CXL (KXL2)
Description: The keratoconus cornea is treated with epithelial debridement in local anesthesia, and then soaked in Riboflavin by repeated topical application every 3 minutes during 10 minutes. The cornea is then irradiated with pulsed ultraviolet light (1s on/1s off) in a topography-based arcuate shape with the Avedro KXL2® with an energy from 7.2-15.0 J/cm2 depending on the severity of the keratoconus.
Study: NCT02192593

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer CBT
Study: NCT02514200

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional pulsed CXL (pCXL)
Description: The keratoconus cornea is treated with epithelial debridement in local anesthesia, and then soaked in Riboflavin by repeated topical application every 3 minutes during 10 minutes. The cornea is then irradiated with pulsed ultraviolet light (1s on/1s off) in a central round 8mm zone with the Avedro KXL2® with an energy of 5.4 J/cm2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin
Description: Riboflavin is added topically immediately before the treatment every 3 minutes during 10 minutes in the eye to be treated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riboflavin
Description: Riboflavin is added topically immediately before the treatment every 3 minutes during 10 minutes in the eye to be treated

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Avedro KXL II
Description: The KXL II™ System crosslinking device from Avedro, Inc. is used for ultraviolet irradiation of the cornea after riboflavin application in both treatment arms.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Avedro KXL II
Description: The KXL II™ System crosslinking device from Avedro, Inc. is used for ultraviolet irradiation of the cornea after riboflavin application in both treatment arms.
Study: NCT00865657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam 3 mg Extended Release Tablets, single dose
Description: A: Experimental Subjects received Alpharma formulated products under non-fasting conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XANAX XR® 3 mg tablets, single dose
Description: B: Active comparator Subjects received Pharmacia \& Upjohn Company formulated products under non-fasting conditions
Study: NCT03013192

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text message reminder
Description: Patients will receive automated text message reminders regarding their physical therapy
Study: NCT01066871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sprifermin (AS902330) 10 mcg
Description: Sprifermin (AS902330) will be administered at a dose of 10 microgram (mcg) as intra-articular injection once every week for 3 consecutive weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sprifermin (AS902330) 30 mcg
Description: Sprifermin (AS902330) will be administered at a dose of 30 mcg as intra-articular injection once every week for 3 consecutive weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sprifermin (AS902330) 100 mcg
Description: Sprifermin (AS902330) will be administered at a dose of 100 mcg as intra-articular injection once every week for 3 consecutive weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to sprifermin (AS902330) will be administered as intra-articular injection once every week for 3 consecutive weeks.
Study: NCT01084538

Intervention type: DRUG
Intervention: Zemplar iv (paricalcitol iv)
Description: Each patient will be treated at the physician's discretion. Zemplar (paricalcitol) will be prescribed in the usual manner in accordance with the approved Summary of Product Characteristics.
Study: NCT00774072

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin (Gernebcin®)
Description: 1 ml / day in each nostril

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tobramycin (Gernebcin®)
Description: 1 ml / day in each nostril
Study: NCT02523404

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: interventional therapy
Description: lung cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: interventional therapy
Description: lung cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
Study: NCT04760535

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Invisalign® First Phase I treatment (Align Technology, Inc., Santa Clara, CA, USA)
Description: Subjects in this arm will be instructed to wear aligners 24h/day for entire duration of the therapy. They will be asked to remove their retainers only while eating, drinking (except water), or cleaning. At the time of appliance delivery, both written and verbal oral hygiene instructions were given, including methods for cleaning appliances themselves. Also, written informed consent were obtained for each patient or the parents.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tooth-borne Hyrax-type maxillary expander
Description: The expansion protocol was one quarter-turn twice a day (0.45 mm activation per day) until overcorrection with the maxillary lingual cusps contacting the mandibular buccal cusps. The expander was left passively for retention for a minimum of 6 months. At the time of appliance delivery, both written and verbal oral hygiene instructions were given, including methods for cleaning appliances themselves. Also, written informed consent were obtained for each patient or the parents.
Study: NCT01570842

Intervention type: OTHER
Group type: OTHER
Intervention: Anthropometric measurements
Description: All participants will have their waist circumference and waist to hip ratio taken as a measurement of central obesity.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tissue samples
Description: Participants undergoing clinically indicated upper endoscopy and who consent to providing tissue samples will have 8 tissue samples taken for future research purposes.
Study: NCT03574038

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Patients will be randomized to active treatment (C-tDCS) vs sham stimulation in a 3:1 ratio. There will be 6 dose tiers, reflecting increasing intensity and duration of stimulation: Tier 1 - 1 mA, single 20 - min cycle; Tier 2- 2 mA, single 20 min cycle; Tier 3 - 1 mA, 2 cycles of 20 min/20 min off; Tier 4- 2 mA, 2 cycles of 20 min/20 min off; Tier 5 - 1 mA, 3 cycles of 20 min/20 min off; Tier 6 - 2 mA, 3 cycles of 20 min/20 min off.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: Patients will be randomized to active treatment (C-tDCS) vs sham stimulation in a 3:1 ratio. Patients in the sham stimulation arm at all the tiers will have the cap and electrodes in place, and sham switch moved but without prolonged delivery of electrical stimulation.
Study: NCT02041780

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Shearwave electrography
Study: NCT02427243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenezumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenezumab
Study: NCT01689363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronidase
Description: Subjects received intradermal injections of 0.02 mL Amphadase® (hyaluronidase 150 USP units/mL) at two random sites on their forearms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Histamine
Description: Subjects received one intradermal injection of 0.02 mL Histatrol® (histamine base 0.1 mg/mL) at one random sites on their forearms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Subjects received one intradermal injection of 0.02 mL saline at one random site on their forearm.
Study: NCT01845805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral azacitidine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation
Study: NCT03080818

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic - Lactobacillus Rhamnosus GG
Description: 2 capsules per day for 90 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 placebo capsules per day for 90 days
Study: NCT00612352

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethanol High Dose, Ethanol Low Dose, and Placebo
Description: Three test days will involve administration of placebo, ethanol high dose (BrAc=100mg%) or ethanol low dose (BrAc=40mg%)intravenously for approximately 20 minutes, until the target BrAc is achieved. Once BrAc is achieved (40mg% or 100mg%) it will be maintained using a clamp procedure for 60 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethanol High Dose, Ethanol Low Dose, and Placebo
Description: Three test days will involve administration of placebo, ethanol high dose (BrAc=100mg%) or ethanol low dose (BrAc=40mg%)intravenously for approximately 20 minutes, until the target BrAc is achieved. Once BrAc is achieved (40mg% or 100mg%) it will be maintained using a clamp procedure for 60 minutes.
Study: NCT02244138

Intervention type: BEHAVIORAL
Intervention: Adolescent CDSS
Description: computer decision support system (CDSS) for health care providers of adolescents in primary care
Study: NCT00167154

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Risperidone and placebo comparator
Description: Up to 2 mg risperidone or matching placebo daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone and placebo comparator
Description: Up to 2 mg risperidone or matching placebo daily
Study: NCT04080713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Budesonide 9 mg prolonged release tablet
Study: NCT00760513

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OMACOR
Description: 4 grammes daily, oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: 4 grammes daily, oral capsule (olive oil)
Study: NCT01589926

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bi-level positive airway pressure device
Description: BiPAP initiated for at least 16 hours per day for a minimum of 48hrs.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham CPAP
Description: Sham CPAP initiated for at least 16 hours per day for a minimum of 48hrs.
Study: NCT02607202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study: NCT00566813

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Islet Cell Transplant
Description: 1-3 allogeneic islet transplants; two doses of basiliximab 20 mg iv.; sirolimus po trough levels 10-15 ng/ml X 3 months, then 7-10 ng/ml; tacrolimus po trough levels 3-6 ng/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Islet Cell Transplant plus
Description: 1-3 allogeneic Islets of Langerhans transplantations; two doses of basiliximab 20 mg iv.; sirolimus po daily to maintatin serum levels 12-15 ng/mL for 3 months, and 7-10 ng/mL thereafter; tacrolimus po twice daily to maintain serum levels 3-6 ng/mL; etanercept 50 mg IV before islet transplant, 25 mg subcutaneously post-transplant days 3, 7, 10; exenatide subcutaneously 5 mcg pre-transplant and twice daily for I week, then increased to 10-mcg twice daily for 6 months after the last islet transplant.
Study: NCT00848848

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent Influenza Vaccine
Description: 1 dose of Trivalent Influenza Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent Influenza Vaccine + high A
Description: 1 dose of Trivalent Influenza Vaccine with high A content

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent Influenza Vaccine + ¼ dose adjuvant
Description: 1 dose of Trivalent Influenza Vaccine plus ¼ dose adjuvant

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent Influenza Vaccine + high A + ¼ dose adjuvant
Description: 1 dose of Trivalent Influenza Vaccine with high A plus ¼ dose adjuvant

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent Influenza Vaccine + ½ dose adjuvant
Description: 1 dose of Trivalent Influenza Vaccine plus ½ dose adjuvant

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent Influenza Vaccine + high A + ½ dose adjuvant
Description: 1 dose of Trivalent Influenza Vaccine with high A plus ½ dose adjuvant

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent Influenza Vaccine + adjuvant
Description: 1 dose of Trivalent Influenza Vaccine plus adjuvant

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent Influenza Vaccine + high A + adjuvant
Description: 1 dose of Trivalent Influenza Vaccine with high A plus adjuvant

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent Influenza Vaccine intradermal dose
Description: 1 dose of Trivalent Influenza Vaccine intradermal dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent Influenza Vaccine + high A intradermal dose
Description: 1 intradermal dose of Trivalent Influenza Vaccine + high A
Study: NCT04661943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucidinostat
Description: Tucidinostat Specification: 5mg / tablet. Dosage: oral, 20 mg (3 tablets) each time, twice a week, with the interval of no less than 3 days (such as Monday and Thursday, Tuesday, Friday, Wednesday and Saturday, etc.)
Study: NCT03544645

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audiovisual material video
Description: an educational video which has content of knowledge, attitude, behavior, and barriers towards insulin therapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Printed material brochure
Description: an educational brochure which has content of knowledge, attitude, behavior, and barriers towards insulin theray.
Study: NCT03923686

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-guided drainage using LAMS with DPS
Description: Endoscopic ultrasound-guided drainage using lumen-apposing metal stent with coaxial plastic stent in the treatment of walled-off pancreatic necrosis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-guided drainage using LAMS alone
Description: Endoscopic ultrasound-guided drainage using lumen-apposing metal stent without coaxial plastic stent in the treatment of walled-off pancreatic necrosis.
Study: NCT01788475

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Ozurdex (dexamethasone) 0.7mg steroid implant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Ozurdex (dexamethasone) 0.7mg steroid implant

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Dexamethasone
Description: Ozurdex (dexamethasone) 0.7mg steroid implant
Study: NCT03637413

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hindmilk
Description: Mother will be taught to separate her milk and infant will receive only hindmilk for feeds
Study: NCT04058470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab, Rituximab
Description: Toripalimab in combination with Rituximab will be administered every 3 weeks up to 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CHOP Protocol
Description: After toripalimab plus rituximab treatment, R-CHOP regimen will be administered every 3 weeks in combination with R-CHOP up to 6 cycles.
Study: NCT01450293

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh63 ME-TRAP, MVA ME-TRAP
Description: 1x10\^10 vp AdCH63 ME-TRAP followed by 1x10\^8 pfu MVA ME-TRAP 8 weeks later. Intramuscular needle injection into the anterolateral thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh63 ME-TRAP, MVA ME-TRAP
Description: 1x10\^10 vp AdCH63 ME-TRAP followed by 1x10\^8 pfu MVA ME-TRAP 8 weeks later. Intramuscular needle injection into the anterolateral thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCH63 ME-TRAP, MVA ME-TRAP
Description: 5x10\^10 vp AdCH63 ME-TRAP followed by 1x10\^8 pfu MVA ME-TRAP 8 weeks later. Intramuscular needle injection into the anterolateral thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCH63 ME-TRAP, MVA ME-TRAP
Description: 5x10\^10 vp AdCH63 ME-TRAP followed by 1x10\^8 pfu MVA ME-TRAP 8 weeks later. Intramuscular needle injection into the anterolateral thigh.
Study: NCT01043094

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pitavastatin 4mg
Description: Pitavastatin 4mg single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin 4mg
Description: Pitavastatin 4mg single dose
Study: NCT04136262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tripterygium wilfordii Hook F (TwHF)
Description: Oral Tripterygium wilfordii Hook F 20mg thrice daily for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Oral methotrexate 10 mg per week for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Oral methotrexate 10 mg per week for 24 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dummy Tripterygium wilfordii Hook F (TwHF)
Description: Oral dummy Tripterygium wilfordii Hook F 20mg thrice daily for 24 weeks.
Study: NCT00765947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren 150 or 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide 12.5 or 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Amlodipine 5 or 10 mg
Study: NCT00850122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cefazolin
Description: Cefazolin dosing - administered for 48 hours Dosage~≤28 days of age 25 mg/kg IV q12 29-120 days of age 25 mg/kg IV q8
Study: NCT01270321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus 10 mg daily continuously (switch to 2-drug combination at progression if no intolerable toxicity)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide
Description: Pasireotide 1200 mcg bid for 4 weeks followed by Pasireotide long acting release (LAR) 60 mg i.m. once every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus and Pasireotide
Description: Everolimus 10 mg daily continuously together with Pasireotide 1200 mcg bid for 4 weeks followed by Pasireotide long acting release (LAR) 60 mg i.m. once every 4 weeks
Study: NCT01875263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cloxacilin
Description: 2g/4 hours i.v., 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cloxacillin
Description: 2g/4h 14 days Standard therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: 500 mg v.o./24h, 9 days